Achieving body weight loss of 515% can improve cardiometabolic parameters including prediabetes, dyslipidemia, and hypertension [5, 9]
Some patients may benefit from transitioning to lower doses of GLP-1 medications rather than complete discontinuation, though this approach requires further research to establish optimal dosing strategies
At microdose levels, this risk is likely minimal, but patients with existing gallbladder disease should be monitored
Pointing out that obesity is more important than cigarette smoking in causing cancer, Bloom argues 'As a physician, I see death
The duration for which an individual stays on Semaglutide GLP-1 for weight loss may vary depending on various factors, including the individuals overall health, response to the medication, and the recommendation of their healthcare provider
Most participants who experienced nausea reported it during the initial weeks and dose escalation periods, with symptoms improving as the body adapted